At the patient interface improving service delivery toward health and welfare benefits
Areas of activity
Our research expertise is encompassed within the following areas of activity:
- Health services research and evaluation
- Education and workforce development
- Pharmacoepidemiology pharmacovigilance
- Health-/Pharmaco-economics
- Quality of life measures
- Inter-professional education
Research interests/expertise
- Development and application of quality-of-life measures to impact practice guidelines, medicines interventions and social care strategies in a neurodegenerative diseases, such as Parkinson’s disease.
- Medication management in care homes - impact of stakeholders on adherence and medication wastage. Discharge from hospital and the role of discharge advice letters (DALs) in the seamless transition and integration into primary care.
- Safe and effective use of medicines including evaluation of pharmacy services, primary/secondary care interface, the skill mix of healthcare teams, spontaneous reporting of adverse drug reactions, transition between the hospital and primary care setting.
- Effectiveness and safety of intravenous parenteral nutrition and injectable medicines
- Non-medical prescribing - barriers and enablers.
- Patient and public involvement in health, science and technology related to pharmacy, medicines and health.
- Education (including Inter-professional Education, IPE) ; Pharmacy Professionalism, Ethics and Law; Evaluating Use and Delivery of Medicines and Healthcare Services.
Academic staff
Researchers in the theme have extensive international and national engagement with external stakeholders.
| Academic staff | Research interests |
|---|---|
| Dr Allan Cosslett (also DDPSET) | Investigating the various aspects of physical and physico-chemical stability of parenteral nutrition admixtures. The application and comparison of particle size analysis equipment. Design and validation of methods and equipment for manufacturing sterile dosage forms and devices. Particulate contamination of intravenous devices and delivery systems. Effectiveness and safety of intravenous lipid emulsions as drug delivery systems. Examination of the effectiveness of intravenous filtration devices. |
| Dr Sion Coulman (also DDPSET) | Development of the microneedle device as a non-invasive method for trans/intra-dermal delivery of novel and existing medicines, and the translation of microneedle technology from a laboratory prototype to a clinically useful device. |
| Dr Rhian Deslandes | Development of the expanding role of pharmacists, such as pharmacist prescribing. The views of heath care professionals and patients on this expanding role, how it is implemented and how it affects practice are of particular interest. |
| Dr William Ford (also DDPSET) | Cannabinoids in the cardiovascular system, cannaboids in the gastro-intestinal tract, pulmonary inflammation, β-adrenoceptor stimulation and myocardial ischaemia-reperfusion injury. |
| Dr Karen Hodson | Director for the MSc in Clinical Pharmacy, an experiential based programme run in approximately 35 hospitals in the UK. Director for the Certificate in Non-medical Prescribing, a joint course for pharmacists, nurses, midwives and other allied health professionals. |
| Dr Louise Hughes | Pharmacovigilance, particularly with regard to the role of the pharmacist in spontaneous reporting of ADRs. Pharmacy education. |
| Professor Dai John | Pharmacy practice and health services research including: legal, ethical and professional aspects of pharmacy, including professional regulation, pharmacy and healthcare education, training and development, including interprofessional education, patient and public involvement in health, science and technology related to pharmacy, medicines and health. |
| Dr Emma Lane also DDPSET) | Parkinson's disease, Huntington's disease, L-dopa-induced dyskinesia, Graft-induced dyskinesia, Huntington's Chorea. |
| Dr Efi Mantzourani | Medicinal chemistry background followed by clinical pharmacy practice, which include medication management and cost-analysis of medication wastage from Medication Administration Record (MAR) in care homes, as well as discharge from hospital and the role of Discharge Advice Letters (DALs) in a seeming transition and integration into primary care. |
| Dr Mathew Smith | Blood brain barrier, phage display, experimental therapeutics. |
| Professor Marjorie Weiss | Communication skills in patient-professional consultations; pharmacist and nurse prescribing; patient and professional decision making about medicines; the evaluation of new pharmacy services; mixed methods research designs. |
| Dr Rowan Yemm | Optimisation of communication between care settings, use of information technology and inter and intra-professional collaboration​ at hospital discharge, medication errors, anti-doping and drugs in sport. |